Skip to content
Dose Brief
Menu
Head-to-head · Brief Score

Invigor Medical vs Remote Pharmacy

Two GLP-1 desks, one scoreboard. We put Invigor Medical and Remote Pharmacy head-to-head on the published Brief Score — the same six factors, scored the same way.

Higher Brief ScoreNo. 9 · Grade B+

Invigor Medical

Visit Invigor Medical Full brief →
vs
No. 209 · Grade C

Remote Pharmacy

Visit Remote Pharmacy Full brief →

The verdict

Invigor Medical takes this head-to-head.

Invigor Medical scores 88 to 66 on our six-factor Brief Score — An established telehealth pharmacy with a broad metabolic and hormone catalog and a steady price line.

That doesn't make Remote Pharmacy a bad call — it's best for people who want low cash-pay compounded glp-1 with no subscription and free shipping. Weigh the six factors below against your own priorities before you decide.

Assume any provider we list may compensate us — we may earn a commission, at no cost to you. It never changes the Brief Score.

Factor by factor

Both desks scored on the six published Brief Score factors. The higher score in each row is marked. See the methodology.

Price Stability
87
78
Supply Reliability
88
68
Transparency
84
52
Access Breadth
82
56
Clinical Oversight
88
74
Track Record
90
63
Invigor MedicalBrief Score 88 · 66Remote Pharmacy

Price, coverage & the tracker

Invigor MedicalRemote Pharmacy
Brief Score88/100 (B+)66/100 (C)
Semaglutide$199/moFrom $167/mo (all doses, compounded)
Tirzepatide$339/moFrom $230/mo (all doses, compounded)
CoverageNot disclosedCoverage not published
Brand-name accessCompounded onlyCompounded only
Oral / sublingualInjection onlyYes
On the trackerStableprice stableNewnew to the tracker, no prior reading

Invigor Medical: Long-running operator; mid-market pricing unchanged this cycle.

Remote Pharmacy: New to the tracker on 1 August 2026. The published line reads From $167/mo (all doses, compounded) at our first reading; there is no earlier reading of ours to compare it against yet.

Not sold on either?

CoreAge Rx tops the whole board at 94/100.

The steadiest desk on the board: one flat, no-step-up price on both molecules, nationwide, and it hasn't moved.

Keep comparing

Pricing, states and access reflect each provider's public disclosures at last review; the Brief Score is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.